Minerva Neurosciences, Inc.

NERV

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$4.84

+$0.05 · +1.04%

Aug 21, 4:00 PM ET

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

43/100

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

Fair Value

Momentum

Neutral

Sentiment

Mixed

Risk resilience

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Minerva Neurosciences, Inc. functions as a biopharmaceutical firm in the clinical development stage, primarily dedicated to uncovering and bringing to market novel therapeutic options for disorders affecting the central nervous system. Its portfolio of experimental treatments notably features roluperidone, an investigational drug aimed at managing schizophrenia, alongside MIN-301, a soluble recombinant variant of the neuregulin-1b1 protein, which is being explored for its potential in treating Parkinson's disease and various other neurodegenerative conditions. The company has a contractual licensing agreement with Mitsubishi Tanabe Pharma Corporation, authorizing the worldwide development, distribution, and import of roluperidone, with the explicit exclusion of the Asian continent. Established in 2007, this organization initially operated as Cyrenaic Pharmaceuticals, Inc. before undergoing a name change to Minerva Neurosciences, Inc. in 2013. Its corporate headquarters are located in Waltham, Massachusetts.

Industry: Biotechnology
Sector: Healthcare
Headquarters: US
CEO: Remy Luthringer
Listed since: Jul 1, 2014
Employees: 7

Market position

Day range

Current $4.84

$4.80$5.07

52-week range

Current $4.84

$1.93$12.46

Open: $4.935
Previous close: $4.79
Volume: 106.45K; 0.47× average
Average volume: 224.76K; Average daily volume
Market cap: 225.49M USD
Beta: -0.11; Market reference 1
50-day average: $4.4519; +8.72% above average
200-day average: $5.033; -3.83% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value: 16.69M USD
P/E (TTM): -0.17×
P/B (TTM): -1.12×
P/S (TTM): 0×
EV / EBITDA: -0.06×
Earnings yield: -862.37%
Free cash flow yield: -39708.52%
Dividend yield: 0.00%

Profitability & efficiency

Gross margin: 0.00%
Operating margin: 0.00%
Net margin: 0.00%
Return on equity: 208.47%
Return on assets: -299.51%
Return on invested capital: -15.79%

Financial health

Debt / equity: 0×
Current ratio: 36.29×

Financial statements

Income trends

Operating income

−15.1M USD+30.87%

Net income

−293.42M USD−294.86M USD

Metric (USD)	FY2025	FY2024	FY2023	FY2022	FY2021
Research and development	5.76M USD	11.9M USD	12.71M USD	14.65M USD	32.04M USD
Selling, general, and administrative	9.34M USD	9.95M USD	10.41M USD	10.58M USD	13.33M USD
Operating expenses	15.1M USD	21.85M USD	23.12M USD	25.23M USD	45.37M USD
Interest income	948.12K USD	1.27M USD	1.44M USD	556.95K USD	16.52K USD
Interest expense	—	4.56M USD	8.28M USD	7.41M USD	6.33M USD
Depreciation and amortization	5.44K USD	22.47K USD	30.98K USD	8.51K USD	101.79K USD
Operating income	−15.1M USD	−21.85M USD	−23.12M USD	−25.23M USD	−45.37M USD
Net income	−293.42M USD	1.44M USD	−30.01M USD	−32.11M USD	−49.91M USD